SLIGRL-NH2PAR2 activator CAS# 171436-38-7 |
- Thrombin Receptor Agonist Peptide
Catalog No.:BCC3950
CAS No.:137339-65-2
- TFLLR-NH2
Catalog No.:BCC3948
CAS No.:197794-83-5
- AY-NH2
Catalog No.:BCC3949
CAS No.:352017-71-1
- ML161
Catalog No.:BCC3642
CAS No.:423735-93-7
- AC 55541
Catalog No.:BCC3951
CAS No.:916170-19-9
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 171436-38-7 | SDF | Download SDF |
PubChem ID | 9831050 | Appearance | Powder |
Formula | C29H56N10O7 | M.Wt | 656.82 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 1 mg/ml in water | ||
Sequence | SLIGRL (Modifications: Leu-6 = C-terminal amide) | ||
Chemical Name | (2S,3S)-2-[[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-N-[2-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]-3-methylpentanamide | ||
SMILES | CCC(C)C(C(=O)NCC(=O)NC(CCCN=C(N)N)C(=O)NC(CC(C)C)C(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CO)N | ||
Standard InChIKey | SGPMJRPYYIJZPC-JYAZKYGWSA-N | ||
Standard InChI | InChI=1S/C29H56N10O7/c1-7-17(6)23(39-27(45)21(12-16(4)5)38-25(43)18(30)14-40)28(46)35-13-22(41)36-19(9-8-10-34-29(32)33)26(44)37-20(24(31)42)11-15(2)3/h15-21,23,40H,7-14,30H2,1-6H3,(H2,31,42)(H,35,46)(H,36,41)(H,37,44)(H,38,43)(H,39,45)(H4,32,33,34)/t17-,18-,19-,20-,21-,23-/m0/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Agonist peptide derived from the N-terminus of protease-activated receptor-2 (PAR2). Activates PAR2 (EC50 ~ 5 μM) and facilitates gastrointestinal transit in mice in vivo. Control peptide LRGILS-NH2 also available. |
SLIGRL-NH2 Dilution Calculator
SLIGRL-NH2 Molarity Calculator
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Agonist peptide derived from the N-terminus of protease-activated receptor-2 (PAR2). Activates PAR2 (EC50 ~ 5 μM) and facilitates gastrointestinal transit in mice in vivo. Control peptide LRGILS-NH2 also available.
- Otophylloside B 4'''-O-beta-D-cymaropyranoside
Catalog No.:BCN7522
CAS No.:171422-85-8
- Otophylloside B 4'''-O-alpha-L-cymaropyranoside
Catalog No.:BCN7511
CAS No.:171422-82-5
- Calcium Gluceptate
Catalog No.:BCC3743
CAS No.:17140-60-2
- Ethyl 4-hydroxyphenylacetate
Catalog No.:BCN3792
CAS No.:17138-28-2
- Delphinidin-3-O-arabinoside chloride
Catalog No.:BCN3021
CAS No.:171370-55-1
- (RS)-AMPA hydrobromide
Catalog No.:BCC6926
CAS No.:171259-81-7
- TAPI-1
Catalog No.:BCC5400
CAS No.:171235-71-5
- Posaconazole
Catalog No.:BCC1103
CAS No.:171228-49-2
- N-Methylquipazine dimaleate
Catalog No.:BCC6697
CAS No.:171205-17-7
- PD 158780
Catalog No.:BCC7434
CAS No.:171179-06-9
- H-Ser(tBu)-OMe.HCl
Catalog No.:BCC3033
CAS No.:17114-97-5
- EGLU
Catalog No.:BCC6871
CAS No.:170984-72-2
- Dammarenediol II 3-O-caffeate
Catalog No.:BCN6519
CAS No.:171438-55-4
- Salprionin
Catalog No.:BCN3162
CAS No.:171439-43-3
- Myrislignan
Catalog No.:BCN1242
CAS No.:171485-39-5
- Alexidine dihydrochloride
Catalog No.:BCC2466
CAS No.:1715-30-6
- Urocortin (rat)
Catalog No.:BCC5789
CAS No.:171543-83-2
- 10,11-Dihydro-24-hydroxyaflavinine
Catalog No.:BCN7440
CAS No.:171569-81-6
- Doederleinic Acid
Catalog No.:BCC8319
CAS No.:171596-14-8
- Tadalafil
Catalog No.:BCC2281
CAS No.:171596-29-5
- Nortadalafil
Catalog No.:BCC1806
CAS No.:171596-36-4
- NBI-98854
Catalog No.:BCC4278
CAS No.:171598-74-6
- Sildenafil Citrate
Catalog No.:BCC2276
CAS No.:171599-83-0
- Sodium Phenylbutyrate
Catalog No.:BCC2164
CAS No.:1716-12-7
Detection of functional receptors for the proteinase-activated-receptor-2-activating polypeptide, SLIGRL-NH2, in rat vascular and gastric smooth muscle.[Pubmed:8564891]
Can J Physiol Pharmacol. 1995 Aug;73(8):1203-7.
We have studied the actions of the proteinase-activated-receptor-2 (PAR2)-activating polypeptide, SLIGRL-NH2 (SLI-NH2), in rat aorta and in gastric longitudinal muscle preparations. In the phenylephrine-precontracted aorta preparation, SLI-NH2 caused an endothelium-dependent relaxation that mimicked the action of low concentrations (0.5 U/mL) of trypsin and that was blocked by the nitric oxide synthase inhibitor N omega-nitro-L-arginine methyl ester. In endothelium-free aorta ring preparation, SLI-NH2 caused neither a relaxation nor a contraction. In the gastric longitudinal muscle preparation, SLI-NH2 caused a transient contraction that mimicked the action of trypsin (0.5 U/mL) and that was sensitive to inhibitors of cyclooxygenase (indomethacin) and tyrosine kinase (genistein). Further, using a reverse-transcriptase - polymerase chain reaction (RT-PCR) approach we detected, in both assay tissues, mRNA for the rat PAR2 receptor, and we ascertained, using a cloned receptor cDNA obtained from a rat intestinal cDNA library, that the putative N-terminal activating peptide sequence of the rat PAR2 receptor (SLIGRL) is identical with the one previously cloned from murine tissue. We concluded that, like the thrombin receptor, the PAR2 receptor may play a pathophysiologic role in the regulation of vascular and gastric smooth muscle contractility.
Scratching behavior in mice induced by the proteinase-activated receptor-2 agonist, SLIGRL-NH2.[Pubmed:16356490]
Eur J Pharmacol. 2006 Jan 20;530(3):281-3.
We examined whether the proteinase-activated receptor-2 (PAR2) agonist, H-Ser-Leu-Ile-Gly-Arg-Leu-NH2 (SLIGRL-NH2), could induce scratching behavior in mice. Intradermal injections of SLIGRL-NH2 (10-50 microg) evoked dose dependent scratching. This behavior peaked near 5 min and returned to preinjection levels within 30 min. Pretreatment of animals with a histamine H1 receptor antagonist, pyrilamine, blocked histamine induced scratching, but it had little effect on SLIGRL scratching. Our study suggests that PAR2 mediates histamine independent itch.
In vivo evidence that protease-activated receptors 1 and 2 modulate gastrointestinal transit in the mouse.[Pubmed:11498505]
Br J Pharmacol. 2001 Aug;133(8):1213-8.
1. Protease-activated receptors (PARs) 1 and 2 modulate the gastric and intestinal smooth muscle motility in vitro. In the present study, we examined if activation of PAR-2 and PAR-1 could alter gastrointestinal transit in mice. 2. Intraperitoneal administration of the PAR-2-activating peptide SLIGRL-NH(2), but not the inactive control LSIGRL-NH(2), at 1 - 5 micromol kg(-1), in combination with the aminopeptidase inhibitor amastatin at 2.5 micromol kg(-1), facilitated gastrointestinal transit in a dose-dependent manner. The human PAR-1-derived peptide SFLLR-NH(2) and the specific PAR-1 agonist TFLLR-NH(2), but not the inactive control FSLLR-NH(2), at 2.5 - 10 micromol kg(-1), in combination with amastatin, also promoted gastrointestinal transit. 3. The Ca2+-activated, small conductance K+ channel inhibitor apamin at 0.01 micromol kg(-1) significantly potentiated the actions of SLIGRL-NH(2) and TFLLR-NH(2) at subeffective doses. 4. The increased gastrointestinal transit exerted by either SLIGRL-NH(2) at 5 micromol kg(-1) or TFLLR-NH(2) at 10 micromol kg(-1) was completely abolished by the L-type Ca2+ channel inhibitor verapamil at 61.6 micromol kg(-1). In contrast, the tyrosine kinase inhibitor genistein at 18.5 micromol kg(-1) failed to modify the effects of the agonists for PAR-2 or PAR-1. 5. These findings demonstrate that PAR-1 and PAR-2 modulate gastrointestinal transit in mice in vivo. Our data also suggest that the PAR-1-and PAR-2-mediated effects are modulated by apamin-sensitive K+ channels and are dependent on activation of L-type Ca2+ channels, but independent of tyrosine kinase. Our study thus provides novel evidence for the physiological and/or pathophysiological roles of PARs 1 and 2 in the digestive systems, most probably during inflammation.
Molecular cloning of a potential proteinase activated receptor.[Pubmed:7937743]
Proc Natl Acad Sci U S A. 1994 Sep 27;91(20):9208-12.
A DNA sequence encoding a G-protein-coupled receptor was isolated from a mouse genomic library. The predicted protein is similar in structure to the thrombin receptor and has a similar activation mechanism. When expressed in Xenopus laevis oocytes, the receptor was activated by low concentrations of trypsin (EC 3.4.21.4) and by a peptide (SLIGRL) derived from the receptor sequence, but was not activated by thrombin (EC 3.4.21.5). Trypsin failed to activate a mutant receptor in which the presumed cleavage site Arg-34-Ser-35 was changed to an Arg-Pro sequence. The agonist peptide (SLIGRL) activated equally well mutant and wild-type receptors. Northern blot analysis demonstrated receptor transcripts in highly vascularized tissues such as kidney, small intestine, and stomach. Because this, to our knowledge, is the second example, besides the thrombin receptor, of a proteolytically activated seven-transmembrane G-protein-coupled receptor, we have provisionally named it proteinase activated receptor 2.